US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.

ABSTRACT:

Objective

To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with penta-refractory multiple myeloma (MM) from the perspective of a third-party payer in the United States (US).

Methods

A budget impact analysis was conducted in one-year increments for the first 3 years after the introduction of selinexor for a private payer or Medicare Part D. Total annual treatment costs (2018 US dollars) were calculated as the sum of drug costs, costs of adverse events (AEs; grade ≥3), along with ongoing best supportive care costs. The number of eligible patients was derived from national epidemiology statistics, healthcare databases, and published literature.

Results

In the base-case analysis, selinexor w

SUBMITTER: Bassali J 

PROVIDER: S-EPMC7310980 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature